Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12238MR)

This product GTTS-WQ12238MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12238MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ200MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ14246MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ1799MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ3363MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ9245MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ7914MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ949MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ2485MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 212
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW